Anakinra, showed reduction of CRP and progressive improvement of respiratory parameters in critically ill patients when administered intravenously and in high doses.34 Recently, Moutsopoulos HM described a patient suffering from CAPS who received Canakinumab 10 days before of being tested positive for SARS-CoV-2. The gene discussed is CRP; the disease is cryopyrin-associated periodic syndrome.